Q32 Bio: positive 36-week Phase 2a data for bempikibart in alopecia areata; registration trial planned H1 2027

Q32 Bio Inc.

Mean percent reduction in SALT score from baseline of 35.3% in mITT analysis at Week 36.
40% (10/25) mITT and 30.3% (10/33) ITT achieved SALT-20; 44% achieved SALT-30 and SALT-50.
No serious adverse events or Grade 3+ treatment-related AEs; mild injection site reaction in 36.3% of patients (4% of doses).
Company paid off remaining $6.8M loan to Silicon Valley Bank on June 24, 2026; loan agreement terminated.
Plans to advance bempikibart into registration-directed program in first half of 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.